IL17A and asthma: In some asthma model experiments, IL-17A counteracted the anti-inflammatory effects of regulatory T cells and led to direct contraction of bronchial smooth muscle cells.[42] Some of these findings led to the conclusion that antibodies against IL-17A are beneficial in reducing neutrophil recruitment, airway remodeling, and hyperresponsiveness.